Efforts to Cap Insulin Costs Continue Amid Ongoing Challenges

Insulin vials and pens are being stored at a Kaiser facility in Downey, California as of March 18, 2023. The insurance industry and lawmakers face a significant challenge: making insulin affordable for individuals like two-year-old Bain Brandon, who relies on it to manage Type 1 diabetes. Despite having health coverage, Bain's family incurs substantial expenses, having recently paid $194 for a month's supply of insulin vials and a backup supply of pens.

A bipartisan group of U.S. senators has introduced the INSULIN Act to cap the monthly out-of-pocket insulin cost at $35 for individuals with private insurance. The proposal also features a pilot program offering more affordable insulin options to uninsured individuals across ten states. This legislative effort builds on the provisions of the 2022 Inflation Reduction Act, which capped insulin costs for Medicare beneficiaries, aiming to address the financial burden on insulin users.

Insulin prices, crucial for regulating blood sugar levels, vary significantly across the U.S., impacting approximately 8.1 million users. While some private insurance holders enjoy low costs, others face significant expenses, including diabetes management supplies. Over half of U.S. states have enacted laws capping insulin co-pays between $25 to $100 monthly for state-regulated plans, yet many still struggle with affordability.

Manufacturers like Eli Lilly, Sanofi, and Novo Nordisk have responded by reducing list prices and expanding affordability programs. Despite these efforts, patients with self-insured plans and the uninsured face barriers to accessing reduced prices, as these plans, which cover 57% of privately insured Americans, are excluded from state cost-caps, according to Matthew Fiedler from the Brookings Institution.

The trade association PhRMA highlights the difficulties imposed by pharmacy benefit managers and insurers, which complicate access and affordability. Chanse Jones of PhRMA has expressed readiness to work with policymakers to ensure cost-saving measures benefit patients directly. This pressing issue continues to garner bipartisan support, as the INSULIN Act demonstrates.

While previous attempts to legislate insulin cost caps, such as the 2022 Senate proposal, have faced obstacles, advocacy for affordable insulin remains steadfast. Young adults, particularly those transitioning from parental coverage, often face insurance challenges. Advocates like Manny Hernandez of The Diabetes Link express optimism, emphasizing the importance of ongoing dialogue with policymakers to prioritize affordable access to vital medications like insulin despite potential legislative distractions.